

Table SI. Comparison of chemotherapy-related AEs in patients with different clinical response to neo-adjuvant chemotherapy.

AEs	SD (n=14)	PR (n=36)	OR (95% CI)	P-value
Myelosuppression			26 (3.48 to 286.30)	0.0003
Yes	13	12		
No	1	24		
Low-albumin			3.03 (0.87 to 9.60)	0.1098
Yes	8	11		
No	6	25		
Hepatic impairment			1.36 (0.33 to 5.80)	0.6968
Yes	3	6		
No	11	30		
Multi-AEs			10.36 (2.55 to 35.00)	0.0009
Yes	10	7		
No	4	29		

CI, Confidence interval; OR, Odds ratio; SD, stable disease; PR, partial response; AEs, adverse effects.

Table SII. Top 10 most predictive features in predictive model of AEs.

AE	Features	Normal range (Unit)
Myelosuppressive	White blood cell	4.0-10.0 (x10 ⁹ /l)
	PLT	101-320 (x10 ⁹ /l)
	eto/cis (EP)	Depends on the body surface area / (mg)
	Weight	/ (kg)
	ToP	64.0-83.0 (g/l)
	Tumor history	/
	doc/lob (DL)	Depends on the body surface area/ (mg)
	Hb	113-151 (g/L)
	Non-complete cycle	Depends on the specific plan and the stage
	eto/lob (EL)	Depends on the body surface area/ (mg)
Low-albumin	ToP	64.0-83.0 (g/l)
	Non-complete cycle	Depends on the specific plan and the stage
	Age	-
	Body mass index	18.5-24.9
	Tumor histology	-
	LYM	0.8-4.0 (x10 ⁹ /l)
	LYM%	20.0-40.0 (%)
	PLT	101-320 (x10 ⁹ /l)
	Thymosin	-
	Hb	113-151 (g/l)
Hepatic impairment	Alanine aminotransferase	5-35 U/l
	pem/oxa (POX)	Depends on the body surface area / (mg)
	doc/cis (DP)	Depends on the body surface area / (mg)
	Tumor histology	-
	tax/cis (TP)	Depends on the body surface area / (mg)
	pem/lob (PL)	Depends on the body surface area / (mg)
	Tumor stage	-
	tax/lob (TL)	Depends on the body surface area / (mg)
	eto/lob (EL)	Depends on the body surface area / (mg)
	Age	-

LYM, lymphocytes; eto, etoposide; cis, cisplatin; doc, docetaxel; lob, lobaplatin; pem, pemetrexed; oxa, oxaliplatin; tax, paclitaxel; AEs, adverse effects; PLT, platelet; ToP, total protein; Hb, hemoglobin.